160 related articles for article (PubMed ID: 37702065)
1. Association of PCSK9 Inhibitor Initiation on Statin Adherence and Discontinuation.
LaFratte C; Peasah SK; Huang Y; Hall D; Patel U; Good CB
J Am Heart Assoc; 2023 Sep; 12(18):e029707. PubMed ID: 37702065
[TBL] [Abstract][Full Text] [Related]
2. PCSK9 inhibition in clinical practice: Treatment patterns and attainment of lipid goals in a large health maintenance organization.
Zafrir B; Egbaria A; Stein N; Elis A; Saliba W
J Clin Lipidol; 2021; 15(1):202-211.e2. PubMed ID: 33243717
[TBL] [Abstract][Full Text] [Related]
3. Patient adherence to fully reimbursed proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) treatment.
Stummer A; Ristl R; Kogler B; Muskovich M; Kossmeier M; Stulnig TM
Wien Klin Wochenschr; 2023 Jul; 135(13-14):375-382. PubMed ID: 36808306
[TBL] [Abstract][Full Text] [Related]
4. In-hospital initiation of PCSK9 inhibitor and short-term lipid control in patients with acute myocardial infarction.
Lou B; Liu H; Luo Y; Jiang GT; Wu H; Wang C; Wu Y; Zhou B; Yuan Z; She J; Liu J
Lipids Health Dis; 2022 Oct; 21(1):105. PubMed ID: 36280861
[TBL] [Abstract][Full Text] [Related]
5. Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: A randomized, controlled trial.
Rubino J; MacDougall DE; Sterling LR; Kelly SE; McKenney JM; Lalwani ND
J Clin Lipidol; 2021; 15(4):593-601. PubMed ID: 34172394
[TBL] [Abstract][Full Text] [Related]
6. Real-World Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous Familial Hypercholesterolemia Patients Referred for Lipoprotein Apheresis.
Matta A; Bongard V; Bouisset F; Taraszkiewicz D; Rabès JP; Ferrières J
Med Sci Monit; 2021 May; 27():e928784. PubMed ID: 33958572
[TBL] [Abstract][Full Text] [Related]
7. Factors associated with time to initiation of a PCSK9 inhibitor after hospital discharge for acute myocardial infarction.
McKinley EC; Bittner VA; Brown TM; Chen L; Colantonio LD; Exter J; Orroth KK; Reading SR; Rosenson RS; Muntner P
J Clin Lipidol; 2022; 16(1):75-82. PubMed ID: 34848176
[TBL] [Abstract][Full Text] [Related]
8. Early Initiation of PCSK9 Inhibitor Therapy Versus Placebo in Patients With Acute Coronary Syndrome: A Systematic Review and Meta-Analysis.
Justino GB; Justino LB; Müller ME; Rocha AV; Mazetto A; Cardoso R; Leucker TM
Am J Cardiol; 2024 Feb; 213():110-118. PubMed ID: 37875235
[TBL] [Abstract][Full Text] [Related]
9. Use of Low-Density Lipoprotein-Lowering Therapies Before and After PCSK9 Inhibitor Initiation.
Rymer JA; Mues KE; Monda KL; Bratton EW; Wirtz HS; Okerson T; Overman RA; Brookhart MA; Muntner P; Wang TY
J Am Heart Assoc; 2020 May; 9(9):e014347. PubMed ID: 32326795
[TBL] [Abstract][Full Text] [Related]
10. NMR-based lipoprotein analysis for patients with severe hypercholesterolemia undergoing lipoprotein apheresis or PCSK9-inhibitor therapy (NAPALI-Study).
Schettler VJ; Muellendorff F; Schettler E; Platzer C; Norkauer S; Julius U; Neumann CL
Ther Apher Dial; 2019 Oct; 23(5):467-473. PubMed ID: 30663261
[TBL] [Abstract][Full Text] [Related]
11. Real-World Outcomes of Proprotein Convertase Subtilisin Kexin-9 Inhibitor Use.
Kim OM; Givens TK; Tang EG; Schimmer JJ; Ramsey T; Boyd K; Delate T
J Cardiovasc Pharmacol; 2023 May; 81(5):339-347. PubMed ID: 36795508
[TBL] [Abstract][Full Text] [Related]
12. Statins and PCSK9 inhibitors: A new lipid-lowering therapy.
Gallego-Colon E; Daum A; Yosefy C
Eur J Pharmacol; 2020 Jul; 878():173114. PubMed ID: 32302598
[TBL] [Abstract][Full Text] [Related]
13. Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study.
Kolovou V; Katsiki N; Makrygiannis S; Mavrogieni S; Karampetsou N; Manolis A; Melidonis A; Mikhailidis DP; Kolovou GD
J Cardiovasc Pharmacol Ther; 2021 Jan; 26(1):51-58. PubMed ID: 32729335
[TBL] [Abstract][Full Text] [Related]
14. PCSK9 Inhibitors and Ezetimibe Monotherapy in Patients Not Receiving Statins: A Meta-Analysis of Randomized Trials.
Benhuri B; Ueyama H; Takagi H; Briasoulis A; Kuno T
Curr Vasc Pharmacol; 2021; 19(4):390-397. PubMed ID: 32767943
[TBL] [Abstract][Full Text] [Related]
15. The need for PCSK9 inhibitors and associated treatment costs according to the 2019 ESC dyslipidaemia guidelines vs. the risk-based allocation algorithm of the 2017 ESC consensus statement: a simulation study in a contemporary CAD cohort.
Blaum C; Seiffert M; Goßling A; Kröger F; Bay B; Lorenz T; Braetz J; Graef A; Zeller T; Schnabel R; Clemmensen P; Westermann D; Blankenberg S; Brunner FJ; Waldeyer C
Eur J Prev Cardiol; 2021 Mar; 28(1):47-56. PubMed ID: 33580772
[TBL] [Abstract][Full Text] [Related]
16. Consensus statement of professional associations on prescribing of PCSK9-inhibitors.
Češka R; Táborský M; Vrablík M
Vnitr Lek; 2019; 64(12):1131-1136. PubMed ID: 30704246
[TBL] [Abstract][Full Text] [Related]
17. Real-world treatment patterns of PCSK9 inhibitors among patients with dyslipidemia in Germany, Spain, and the United Kingdom.
Tai MH; Shepherd J; Bailey H; Williams N; Hatz M; Campos Tapias I; Catterick D; Worth G
Curr Med Res Opin; 2019 May; 35(5):829-835. PubMed ID: 30289004
[TBL] [Abstract][Full Text] [Related]
18. Treatment patterns and patient characteristics among early initiators of PCSK9 inhibitors.
Hines DM; Rane P; Patel J; Harrison DJ; Wade RL
Vasc Health Risk Manag; 2018; 14():409-418. PubMed ID: 30573963
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness, Safety, and Adherence to Treatment of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Real Practice.
Gayoso-Rey M; Díaz-Trastoy O; Romero-Ventosa EY; García-Beloso N; González-Freire L; Lorenzo-Lorenzo K; Mantiñán-Gil B; Palmeiro-Carballeira R; Bravo-Amaro M; López-Gil-Otero MDM; Martínez-Reglero C; Crespo-Diz C; Fernández-Catalina P; Piñeiro Corrales G
Clin Ther; 2021 Apr; 43(4):e111-e121. PubMed ID: 33712271
[TBL] [Abstract][Full Text] [Related]
20. Discordant response of low-density lipoprotein cholesterol and lipoprotein(a) levels to monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9.
Edmiston JB; Brooks N; Tavori H; Minnier J; Duell B; Purnell JQ; Kaufman T; Wojcik C; Voros S; Fazio S; Shapiro MD
J Clin Lipidol; 2017; 11(3):667-673. PubMed ID: 28506388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
